Join the Adlyxin group to help and get support from people like you.
Adlyxin News
Small Study Suggests Ozempic Relative May Slow Parkinson's
THURSDAY, April 4, 2024 – Could a medication similar to the blockbuster weight-loss drugs Ozempic and Wegovy slow the ravages of Parkinson's disease? A new, small study suggests it could: Over the...
Lixisenatide Reduces Motor Disability Progression in Parkinson Disease
THURSDAY, April 4, 2024 – For patients with Parkinson disease, lixisenatide yields less progression of motor disability than placebo, according to a study published in the April 4 issue of the New...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
Addition of GLP1-RA Tied to Lower MACE, Heart Failure Risk in Those With Diabetes
FRIDAY, May 12, 2023 – For individuals with diabetes without preexisting cardiovascular disease, the addition of glucagon-like peptide 1 receptor agonists (GLP1-RA) is associated with a lower risk...
Sanofi Receives FDA Approval of Soliqua 100/33 (insulin glargine and lixisenatide) for the Treatment of Adults with Type 2 Diabetes
PARIS, Nov. 21, 2016 /PRNewswire-USNewswire/ – Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua 100/33 (insulin glargine & lixisenatide injection)...
Sanofi Receives FDA Approval of Adlyxin (lixisenatide) for Treatment of Adults With Type 2 Diabetes
PARIS, July 27, 2016 /PRNewswire/ – Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Adlyxin (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection...
Ask a question
To post your own question to this support group, sign in or create an account.